Your browser doesn't support javascript.
loading
The role of real-world evidence for regulatory and public health decision-making for Accelerated Vaccine Deployment- a meeting report.
Bollaerts, Kaatje; Wyndham-Thomas, Chloé; Miller, Elizabeth; Izurieta, Hector S; Black, Steve; Andrews, Nick; Rubbrecht, Michelle; Van Heuverswyn, Fran; Neels, Pieter.
Affiliation
  • Bollaerts K; P95 Epidemiology & Pharmacovigilance, Leuven, Belgium.
  • Wyndham-Thomas C; P95 Epidemiology & Pharmacovigilance, Leuven, Belgium.
  • Miller E; London School of Hygiene and Tropical Medicine (LSHTM), United Kingdom.
  • Izurieta HS; U.S. Food and Drug Administration (FDA), United States.
  • Black S; Global Vaccine Data Network (GVDN), New Zealand.
  • Andrews N; UK Health Security Agency (UKHSA), United Kingdom.
  • Rubbrecht M; P95 Epidemiology & Pharmacovigilance, Leuven, Belgium.
  • Van Heuverswyn F; Flanders Vaccine, Belgium.
  • Neels P; International Alliance of Biological Standardization (IABS-EU), Belgium. Electronic address: pieter.neels@vaccine-advice.be.
Biologicals ; 85: 101750, 2024 Feb.
Article in En | MEDLINE | ID: mdl-38360428
ABSTRACT
The COVID-19 pandemic underscored the need for rapid evidence generation to inform public health decisions beyond the limitations of conventional clinical trials. This report summarises presentations and discussions from a conference on the role of Real-World Evidence (RWE) in expediting vaccine deployment. Attended by regulatory bodies, public health entities, and industry experts, the gathering was a collaborative exchange of experiences and recommendations for leveraging RWE for vaccine deployment. RWE proved instrumental in refining decision-making processes to optimise dosing regimens, enhance guidance on target populations, and steer vaccination strategies against emerging variants. Participants felt that RWE was successfully integrated into lifecycle management, encompassing boosters and safety considerations. However, challenges emerged, prompting a call for improvements in data quality, standardisation, and availability, acknowledging the variability and potential inaccuracies in data across diverse healthcare systems. Regulatory transparency should also be prioritised to foster public trust, and improved collaborations with governments are needed to streamline data collection and navigate data privacy regulations. Moreover, building and sustaining resources, expertise, and infrastructure in LMICs emerged as imperative for RWE-generating capabilities. Continued stakeholder collaboration and securing adequate funding emerged as vital pillars for advancing the use of RWE in shaping responsive and effective public health strategies.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Vaccines / Pandemics Type of study: Guideline / Prognostic_studies Limits: Humans Language: En Journal: Biologicals Journal subject: ALERGIA E IMUNOLOGIA Year: 2024 Type: Article Affiliation country: Belgium

Full text: 1 Database: MEDLINE Main subject: Vaccines / Pandemics Type of study: Guideline / Prognostic_studies Limits: Humans Language: En Journal: Biologicals Journal subject: ALERGIA E IMUNOLOGIA Year: 2024 Type: Article Affiliation country: Belgium